Analyst Reco. Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
3.42 ^USD	0.00%		-5.79%	-20.28%

04-03	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT
04-03	Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	04-03	MT
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	04-03	MT
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	03-26	MT
Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	11-15	MT
Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	06/10/23	MT
Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating	11/08/23	MT
JMP Securities Adjusts Price Target on Sutro Biopharma to $17 From $20, Maintains Market Outperform Rating	03/04/23	MT
HC Wainwright Adjusts Price Target on Sutro Biopharma to $16 From $20, Keeps Buy Rating	31/03/23	MT
Truist Securities Adjusts Sutro Biopharma's Price Target to $25 From $21, Keeps Buy Rating	13/01/23	MT
Piper Sandler Adjusts Price Target on Sutro Biopharma to $18 From $16, Maintains Overweight Rating	10/01/23	MT
HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating	09/11/22	MT
Truist Securities Adjusts Sutro Biopharma Price Target to $21 From $37, Maintains Buy Rating	23/08/22	MT
Berenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Rating	09/08/22	MT
Piper Sandler Reduces Sutro Biopharma's Price Target to $14 From $29, Reiterates Overweight Rating	23/05/22	MT
Piper Sandler Adjusts Sutro Biopharma Price Target to $14 From $29, Maintains Overweight Rating	23/05/22	MT
Wedbush Cuts Sutro Biopharma's Price Target to $20 From $30, Citing Launch Timelines, Cost of Capital; Outperform Rating Kept	10/05/22	MT
JMP Securities Adjusts Sutro Biopharma's Price Target to $20 From $28, Maintains Market Outperform Rating	07/03/22	MT
Wedbush Cuts Sutro Biopharma's Price Target to $30 From $37, Citing Adjusted Timelines for STRO-001, -002; Outperform Rating Kept	06/01/22	MT
Sutro Early-Stage Ovarian Cancer Study Shows 33% Objective Response Rate -- Shares Drop in Pre-Market Trading	06/01/22	MT
Sutro Says Interim Data From STRO-002 Early-Stage Study Shows 33% Objective Response Rate -- Shares Drop After-Hours	05/01/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Analyst Reco.

Filters